Karachi: Abbott Laboratories (Pakistan) Limited has scheduled a virtual board meeting on August 27, 2025, to review the half-yearly financial accounts ending June 30, 2025. The company’s management announced this development on August 20, 2025, with specific details concerning trading restrictions.

In alignment with the Pakistan Stock Exchange (PSX) regulations, Abbott Laboratories has declared a “Close Period” effective from August 20, 2025, until the conclusion of the board meeting on August 27, 2025. During this period, key company stakeholders, including directors, the CEO, and executives, are prohibited from engaging in any trading activities involving the company’s shares.

According to information available from the Pakistan Stock Exchange (PSX), this measure is a standard procedure intended to prevent insider trading and ensure transparency as the company’s financial data is analyzed during the board meeting. The outcome of this meeting will provide insights into Abbott Laboratories’ performance for the first half of 2025.

The company has requested that the information be communicated to the certificate holders on the exchange, maintaining adherence to regulatory standards. Abbott Laboratories operates within the designated market category of healthcare and pharmaceuticals.